Is this your firm? Get featured or correct your listing →
At a glance
OrbiMed Advisors appears in 2 funding rounds tracked by ValueAddVC since 2025, leading 1. Its most recent tracked deal was Biobeat's $50M Series B round (Dec 30, 2025). ValueAddVC also tracks 2 funds managed by OrbiMed Advisors.
Strategy
Recent changes
- Sep 5, 2026Sep 5, 2026Stages updated: Seed, Series A, Growth, Late Stage orbimed.com
- Sep 5, 2026Sep 5, 2026Sectors updated: Biopharmaceuticals, Medical Devices, Digital Health, Diagnostics, Healthcare Services orbimed.com
- Nov 5, 2025Nov 5, 2025Invested in Braveheart Bio (Series A, $185M) PR Newswire
- Jun 1, 1998Jun 1, 1998New fund: OrbiMed Advisors Fund II SEC EDGAR Form D
- Jan 1, 1993Jan 1, 1993New fund: OrbiMed Partners SEC EDGAR Form D
Funds
2| Fund | Vintage | Size | Strategy | Source |
|---|---|---|---|---|
| OrbiMed Advisors Fund II | 1998 | — | Flagship | As of Jul 10, 2026SEC EDGAR Form D |
| OrbiMed Partners | 1993 | — | Flagship | As of Jul 14, 2017SEC EDGAR Form D |
Portfolio
8 totalRecent Investment Activity
2Track record: led 1 and participated in 1 of 2 tracked venture rounds · 2 in the last 12 months · led 1 Series B
| Date | Company | Event | Role | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|---|
| Dec 30, 2025 | Biobeat | Series B | Led | $50M | — | Refresh Miami | |
| Nov 5, 2025 | Braveheart Bio | Series A | Participated | $185M | — | PR Newswire |
Sector / Stage Activity
Co-Investors
12Similar Firms
overlapping sector, stage or regionLatest Pulse
- Oct 15, 2026OrbiMed Raises $3B Across Two New Healthcare FundsOrbiMed closed $3 billion across two new vehicles, OrbiMed Private Investments X for US and European life sciences venture capital and OrbiMed Asia Partners VI for Asian healthcare growth equity, bringing the firm's total assets past $21 billion.→
- Jul 7, 2026FORE Biotherapeutics Raises $67.4M to Push BRAF Cancer DrugFORE Biotherapeutics closed an upsized $67.4 million Series D-2 extension, bringing its total Series D-2 to $110 million, to fund late-stage development of plixorafenib toward a targeted 2027 FDA submission for BRAF-mutated tumors.→
OrbiMed Advisors FAQ
What companies has OrbiMed Advisors invested in?
OrbiMed Advisors' portfolio includes Iambic Therapeutics, World Labs, ADARx, Braveheart Bio, Scribe Therapeutics, Triveni Bio, and 2 more tracked companies.
Who does OrbiMed Advisors co-invest with most?
In the rounds Value Add tracks, OrbiMed Advisors most often invests alongside Ascenta Capital (4 shared deals), Andreessen Horowitz (3 shared deals), Fidelity Investments (2 shared deals), Nvidia (2 shared deals), Abingworth (1 shared deal).
Sources & methodologyshow
- PR Newswireprimary source1 fact
- SEC EDGAR Form Dprimary source1 fact
- SEC EDGAR Form Dprimary source1 fact
- Refresh Miamimajor outlet1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.